TB Guidelines

Treatment

Treatment Guidelines
Title	Format	Date Published
MMWR /Medscape free CE credit on the updated 2020 latent TB infection treatment guidelines.external icon Registration may be required.		2/20/2020
Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020 MMWR Recomm Rep 2020; 69(No. RR-1): 1-11.	PDFpdf icon (337 KB)	2/20/2020
Treatment of Drug-Resistant Tuberculosis American Journal of Respiratory and Critical Care Medicine, 2019 Full Guidelinesexternal icon	Executive Summary PDFpdf icon (731 KB)Full Guidelines PDFpdf icon (1 MB)	9/1/2019
Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection MMWR 2018;67:723-726	PDFpdf icon (94 KB)	6/1/2018
Treatment of Drug-Susceptible Tuberculosis Executive Summaryexternal icon Full Guidelinesexternal icon Clinical Infectious Disease 2016 Table 3. Doses of Antituberculosis Drugs for Adults and ChildrenExternalexternal icon Highlights from the 2016 Treatment of Drug-Susceptible Tuberculosis Guidelines	PDFpdf icon (1 MB)	8/1/2016
Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis MMWR 2013;62 (No. 9)	PDFpdf icon (411 KB)	10/1/2013
Managing Drug Interactions in the Treatment of HIV-Related Tuberculosis June 2013	PDFpdf icon (492 KB)	6/1/2013
Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC MMWR 2005; 54 (No. RR-15, 1-37)	PDFpdf icon (544 KB)	12/1/2005
Treating Opportunistic Infections Among HIV-Exposed and Infected Children MMWR 2004; 53 (RR14)	PDFpdf icon (742 KB)	12/1/2004
Tuberculosis Associated with Blocking Agents Against Tumor Necrosis Factor – Alpha – California, 2002–2003 MMWR 2004; 53 (No. 30)	PDFpdf icon (325 KB)	12/1/2004
N otice to Readers: Updated Guidelines for the Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors MMWR 2004; 53 (No. 2)	PDFpdf iconpdf icon (349 KB)	1/1/2004
Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection MMWR 2003; 52 (No. 31).	PDFpdf icon (587 MB)	8/1/2003

Page last reviewed: October 23, 2020

Content source: Division of Tuberculosis Elimination